Contineum Therapeutics, INC 10-Q quarterly reports

Contineum Therapeutics reports reduced operating expenses and increased cash reserves in Q2 2026, while advancing clinical trials for its lead drug candidates.

Contineum Therapeutics reports reduced R&D expenses and a net loss of $14.5 million for Q1 2026, with cash reserves projected to last over 12 months.

Contineum Therapeutics reported increased net losses in Q3 2025 and for the nine months ended September 30, 2025, while advancing its lead drug candidates PIPE-791 and PIPE-307 with key clinical trial milestones expected.

Contineum Therapeutics reports increased R&D expenses and net loss in Q2 2025, driven by active clinical trial progression for its neuroscience, inflammation, and immunology drug candidates.

Contineum Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and research and development activities.

Contineum Therapeutics reports a net loss of $10.3 million for the third quarter of 2024, with ongoing clinical trials and research and development activities.

Contineum Therapeutics reports a net loss of $9 million for the second quarter of 2024, with significant increases in research and development and general and administrative expenses, offset by interest income and the absence of prior year license revenue.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, released its first quarter 2024 financial results, highlighting ongoing clinical trials and research and development activities.